Christoph Bock

CeMM Research Center for Molecular Medicine, Medical University of Vienna

Biography

Christoph Bock is a Principal Investigator at CeMM and Professor of [Bio]Medical Informatics at the Medical University of Vienna. His research combines experimental biology (single-cell sequencing, epigenetics, CRISPR screening, synthetic biology) with computational methods (bioinformatics, machine learning, artificial intelligence) – for cancer, immunology, and precision medicine. Christoph Bock is also scientific coordinator of the Biomedical Sequencing Facility at CeMM, member of the Human Cell Atlas Organizing Committee, fellow of the European Lab for Learning and Intelligent Systems, and elected board member of the Young Academy in the Austrian Academy of Sciences. He has received important research awards, including an ERC Starting Grant (2016-2021), ERC Consolidator Grant (2021-2026), the Otto Hahn Medal of the Max Planck Society (2009), the Overton Prize of the International Society for Computational Biology (2017), and the Erwin Schrödinger Prize of the Austrian Academy of Sciences (2022). He has been listed among the world’s “Highly Cited Researchers” (ISI) since 2019. He co-founded two startup companies in Vienna: Myllia Biotechnology (providing CROP-seq technology) and Neurolentech.

Relevant Publications

High-content CRISPR screening

Bock C., Datlinger P., Chardon F., Coelho M.A., Dong M.B., Lawson K.A., Lu T., Maroc L., Norman T.M., Song B., Stanley G., Chen S., Garnett M., Li W., Moffat J., Qi L.S., Shapiro R.S., Shendure J., Weissman J.S., Zhuang X., Nature Reviews Methods Primers (2022).
The Organoid Cell Atlas

Bock C., Boutros M., Camp J.G., Clarke L., Clevers H., Knoblich J.A., Liberali P., Regev A., Rios A.C., Stegle O., Stunnenberg H.G., Teichmann S.A., Treutlein B., Vries R.G.J., Human Cell Atlas Biological Network Organoids, Nature Biotechnology (2020).
Ultra-high-throughput single-cell RNA sequencing and perturbation screening with combinatorial fluidic indexing

Datlinger P., Rendeiro A.F.#, Boenke T., Senekowitsch M., Krausgruber T., Barreca D., Bock C., Nature Methods (2021).
Pooled CRISPR screening with single-cell transcriptome readout

Datlinger P., Schmidl C., Rendeiro A., Krausgruber T., Traxler P., Klughammer J., Schuster L., Kuchler A., Alpar D., Bock C., Nature Methods (2017).
Knowledge-primed neural networks enable biologically interpretable deep learning on single-cell sequencing data

Fortelny N., Bock C., Genome Biology (2020).
The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space

Klughammer J., Kiesel B.#, et al., Woehrer A.#, Bock C., Nature Medicine (2018).
Structural cells are key regulators of organ-specific immune response

Krausgruber T., Fortelny N.#, Fife-Gernedl V., Senekowitsch M., Schuster L., Nemc A., Schmidl C., Rendeiro A.F., Lercher A., Bergthaler A., Bock C., Nature (2020).
Single-cell and spatial transcriptomics identify aberrant developmental programs driving granuloma formation

Krausgruber T., Redl A.#, Barreca D.#, Doberer K., Romanovskaia D., Dobnikar L., Guarini M., Unterluggauer L., Kleissl L., Atzmüller D., Mayerhofer C., Kopf A., Saluzzo S., Lim C.X., Rexie P., Weichhart T., Bock C.*, Stary G.*, Immunity (2023).
Chromatin mapping and single-cell immune profiling defines the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia

Rendeiro A.F., Krausgruber T.#, Fortelny N., Zhao F., Penz T., Farlik M., Schuster L.C., Kuchler A., Tasnády S., Réti M., Zoltán M., Alpar D.#, Bödör C.#, Schmidl C.#, Bock C., Nature Communications (2020).
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL

Schmidl C., Vladimer G.I.#, Rendeiro A.F.#, Schnabl S.#, et al., Shehata M.#, Superti-Furga G.#, Jäger U.#, Bock C., Nature Chemical Biology (2019).